4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
The primary objective of this Clinical Investigation is to evaluate the diagnostic yield using the Ion Endoluminal System when used with adjunctive 3D imaging modalities for the biopsy of peripheral pulmonary nodules (PPNs). In a first phase, the…
The primary objective of this Clinical Investigation is to evaluate the diagnostic yield using the Ion Endoluminal System when used with adjunctive 3D imaging modalities for the biopsy of peripheral pulmonary nodules (PPNs). In a first phase, the…